Russell G. Greig is a businessperson who has been at the helm of 18 different companies. Presently, Dr. Greig is Chairman for AM-Pharma Holding BV, Chairman for Sanifit Therapeutics SA, Chairman at Sanifit, Inc. (a subsidiary of Sanifit Therapeutics SA), Chairman for Mint Solutions Holding BV, Chairman at eTheRNA immunotherapies NV and Chairman at BiomX, Inc., Chairman at BiomX Ltd. (a subsidiary of BiomX, Inc.).
He is also on the board of Edinburgh BioQuarter and Member of Scottish Science Advisory Council.
In the past he occupied the position of Chairman of Merus NV, Chairman for Bird Rock Bio, Inc., Chairman of AM-Pharma BV, Chairman for Horama SA, Chief Executive Officer at Genocea Biosciences, Inc., President-Pharmaceuticals International at GlaxoSmithKline Plc President for GSK Equity Investments Ltd and Managing Director & General Manager at Smithkline Beecham Plc (both are subsidiaries of GlaxoSmithKline Plc), Venture Partner at Kurma Partners SA, Chairman at Novavax AB, Chairman at Ablynx NV, Chairman-Supervisory Board at Novagali Pharma SA, Chairman at Bionor Pharma ASA and Chairman at Ipsen Bioinnovation Ltd.
He received a doctorate and an undergraduate degree from The University of Manchester.